Media
News
Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.
Health Canada grants authorization for Bayer’s HYRNUO™ (sevabertinib) for previously treated patients with locally advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC)
Bayer investing more than $45M CAD to build world class Canola Research and Development facility in Canada
Bayer Crop Science Canada Launches Convintro® Corn 12 Herbicide – the first Group 12 available to Combat Multi-Resistant Weeds in Eastern Canada
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
Bayer Crop Science Canada Expands Herbicide Solutions Huskie® PRE and Velocity® m3 in Eastern Canada
Bayer Inc. announced that JIVI® (Antihemophilic Factor [Recombinant, B-domain deleted, PEGylated]) is now authorized for use in patients 7 to under 12 years of age with hemophilia A (congenital Factor VIII deficiency).